- Home
- CHKP vs BIIB Comparison
CHKP vs BIIB Comparison
Compare CHKP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHKP
- BIIB
- Stock Information
- Founded
- CHKP 1993
- BIIB 1978
- Country
- CHKP Israel
- BIIB United States
- Employees
- CHKP N/A
- BIIB N/A
- Industry
- CHKP Computer Software: Prepackaged Software
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CHKP Technology
- BIIB Health Care
- Exchange
- CHKP Nasdaq
- BIIB Nasdaq
- Market Cap
- CHKP 24.2B
- BIIB 19.9B
- IPO Year
- CHKP 1996
- BIIB 1991
- Fundamental
- Price
- CHKP $216.75
- BIIB $124.40
- Analyst Decision
- CHKP Buy
- BIIB Buy
- Analyst Count
- CHKP 25
- BIIB 27
- Target Price
- CHKP $235.09
- BIIB $220.50
- AVG Volume (30 Days)
- CHKP 1.0M
- BIIB 1.8M
- Earning Date
- CHKP 04-23-2025
- BIIB 04-23-2025
- Dividend Yield
- CHKP N/A
- BIIB N/A
- EPS Growth
- CHKP 5.07
- BIIB 40.28
- EPS
- CHKP 7.46
- BIIB 11.18
- Revenue
- CHKP $2,565,000,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- CHKP $8.27
- BIIB N/A
- Revenue Next Year
- CHKP $5.62
- BIIB N/A
- P/E Ratio
- CHKP $30.56
- BIIB $11.75
- Revenue Growth
- CHKP 6.22
- BIIB N/A
- 52 Week Low
- CHKP $145.75
- BIIB $128.51
- 52 Week High
- CHKP $234.36
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- CHKP 49.10
- BIIB 32.01
- Support Level
- CHKP $223.85
- BIIB $128.75
- Resistance Level
- CHKP $231.06
- BIIB $144.07
- Average True Range (ATR)
- CHKP 5.35
- BIIB 3.72
- MACD
- CHKP -0.88
- BIIB -1.21
- Stochastic Oscillator
- CHKP 13.40
- BIIB 11.38
About CHKP Check Point Software Technologies Ltd.
Check Point Software Technologies is a pure-play cybersecurity vendor. The company offers solutions for network, endpoint, cloud, and mobile security in addition to security management. Check Point, a software specialist, sells to enterprises, businesses, and consumers. Around 50% of revenue is generated in Europe, the Middle East, and Africa, 40% from the Americas, and 10% from the Asia-Pacific region. The firm, based in Tel Aviv, Israel, was founded in 1993 and has about 5,000 employees.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.